Anti-platelet therapy for acute coronary syndrome: A review of currently available agents and what the future holds

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 11, Issue 2, 2011, Pages 79-86

  Syed, F A ^a   Bett, J H N ^a   Walters, D L ^a  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

Acute coronary syndrome; Aspirin; Atopaxar; Cangrelor; Clopidogrel; Elinogrel; Prasugrel; Ticagrelor; Vorapaxar

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATOPAXAR; CANGRELOR; CLOPIDOGREL; ELINOGREL; HEPARIN; PLACEBO; PRASUGREL; TICAGRELOR; TICLOPIDINE; TIROFIBAN; VORAPAXAR;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BONE MARROW APLASIA; BRADYCARDIA; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG TRANSFORMATION; DYSPNEA; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; LIVER DYSFUNCTION; LOADING DRUG DOSE; LOW DRUG DOSE; MICROANGIOPATHIC THROMBOCYTOPENIA; NEUTROPENIA; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SIDE EFFECT; STROKE; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; ANALOGS AND DERIVATIVES;

ACUTE CORONARY SYNDROME; ASPIRIN; HUMANS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 83455247332     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152911798347007     Document Type: Article

References (74)

1. Husted, S.; Emanuelsson, H.; Heptinstall, S.; Sandset, P.M.; Wickens, M.; Peters, G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur. Heart J., 2006, 27(9), 1038-1047.
2. Anderson, J.L.; Adams, C.D.; Antman, E.M.; Bridges, C.R.; Califf, R.M.; Casey, D.E.; Jr., Chavey, W.E.; 2nd, Fesmire, F.M.; Hochman, J.S.; Levin, T.N.; et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-STElevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J. Am. Coll. Cardiol., 2007, 50(7), e1-e157.
3. Bassand, J.P.; Hamm, C.W.; Ardissino, D.; Boersma, E.; Budaj, A.; Fernandez-Aviles, F.; Fox, K.A.; Hasdai, D.; Ohman, E.M.; Wallentin, L. et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J., 2007, 28(13), 1598-1660.
4. Kushner, F.G.; Hand, M.; Smith, S.C.; Jr., King, S.B.; 3rd, Anderson, J.L.; Antman, E.M.; Bailey, S.R.; Bates, E.R.; Blankenship, J.C.; Casey, D.E.; Jr. et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with STelevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol., 2009, 54(23), 2205-2241.
5. Van de Werf, F.; Bax, J.; Betriu, A.; Blomstrom-Lundqvist, C.; Crea, F.; Falk, V.; Filippatos, G.; Fox, K.; Huber, K.; Kastrati, A.; et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur. Heart J., 2008, 29(23), 2909-2945.
6. Steinhubl, S.R.; Berger, P.B.; Mann, J.T.; 3rd, Fry, E.T.; DeLago, A.; Wilmer, C.; Topol, E.J. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA, 2002, 288(19), 2411-2420.
7. Sabatine, M.S.; Cannon, C.P.; Gibson, C.M.; Lopez-Sendon, J.L.; Montalescot, G.; Theroux, P.; Claeys, M.J.; Cools, F.; Hill, K.A.; Skene, A.M.; et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. The New England journal of medicine, 2005, 352(12), 1179-1189.
8. Yusuf, S.; Zhao, F.; Mehta, S.R.; Chrolavicius, S.; Tognoni, G.; Fox, K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The New England journal of medicine, 2001, 345(7), 494-502.
9. Chen, Z.M.; Jiang, L.X.; Chen, Y.P.; Xie, J.X.; Pan, H.C.; Peto, R.; Collins, R.; Liu, L.S. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebocontrolled trial. Lancet, 2005, 366(9497), 1607-1621.
10. Bell, B.; Walters, D.; Spaulding, C. Deciphering dual antiplatelet therapy in the era of drug-eluting coronary stents. Curr. drug targets, 2009, 10(6), 519-529.
11. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (Clinical research ed), 2002, 324(7329), 71-86.
12. Mehta, S.R.; Bassand, J.P.; Chrolavicius, S.; Diaz, R.; Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. The New England journal of medicine, 2010, 363(10), 930-942.
13. Silberman, S.; Neukirch-Stoop, C.; Steg, P.G. Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. J. Am. Cardiol., 2005, 95(4), 509-510.
14. Cattaneo, M. P2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agents. Eur. Heart J., 2006, 27(9), 1010-1012.
15. Quinn, M.J.; Fitzgerald, D.J. Ticlopidine and clopidogrel. Circulation, 1999, 100(15), 1667-1672.
16. Montalescot, G.; Sideris, G.; Meuleman, C.; Bal-dit-Sollier, C.; Lellouche, N.; Steg, P.G.; Slama, M.; Milleron, O.; Collet, J.P.; Henry, P., et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J. Am. Coll. Cardiol., 2006, 48(5), 931-938.
17. von Beckerath, N.; Taubert, D.; Pogatsa-Murray, G.; Schomig, E.; Kastrati, A.; Schomig, A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation, 2005, 112(19), 2946-2950.
18. Dangas, G.; Mehran, R.; Guagliumi, G.; Caixeta, A.; Witzenbichler, B.; Aoki, J.; Peruga, J.Z.; Brodie, B.R.; Dudek, D.; Kornowski, R.; et al. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J. Am. Coll. Cardiol., 2009, 54(15), 1438-1446.
19. Stone, G.W.; McLaurin, B.T.; Cox, D.A.; Bertrand, M.E.; Lincoff, A.M.; Moses, J.W.; White, H.D.; Pocock, S.J.; Ware, J.H.; Feit, F., et al. Bivalirudin for patients with acute coronary syndromes. The New England journal of medicine, 2006, 355(21), 2203-2216.
20. Angiolillo, D.J.; Bernardo, E.; Ramirez, C.; Costa, M.A.; Sabate, M.; Jimenez-Quevedo, P.; Hernandez, R.; Moreno, R.; Escaned, J.; Alfonso, F.; et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J. Am. Coll. Cardiol., 2006, 48(2), 298-304.
21. Angiolillo, D.J.; Shoemaker, S.B.; Desai, B.; Yuan, H.; Charlton, R.K.; Bernardo, E.; Zenni, M.M.; Guzman, L.A.; Bass, T.A.; Costa, M.A. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation, 2007, 115(6), 708-716.
22. Serebruany, V.L.; Malinin, A.I.; Pokov, A.; Barsness, G.; Hanley, D.F. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial. American heart journal, 2008, 155(1), 93 e91-97.
23. Nguyen, T.A.; Diodati, J.G.; Pharand, C. Resistance to clopidogrel: a review of the evidence. J. Am. Coll. Cardiol., 2005, 45(8), 1157-1164.
24. Holmes, D.R.; Jr., Dehmer, G.J.; Kaul, S.; Leifer, D.; O'Gara, P.T.; Stein, C.M. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J. Am. Coll. Cardiol., 2010, 56(4), 321-341.
25. Gurbel, P.A.; Bliden, K.P.; Butler, K.; Antonino, M.J.; Wei, C.; Teng, R.; Rasmussen, L.; Storey, R.F.; Nielsen, T.; Eikelboom, J.W.; et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation, 2010, 121(10), 1188-1199.
26. Price, M.J.; Berger, P.B.; Teirstein, P.S.; Tanguay, J.F.; Angiolillo, D.J.; Spriggs, D.; Puri, S.; Robbins, M.; Garratt, K.N.; Bertrand, O.F.; et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA, 2011, 305(11), 1097-1105.
27. Mistry, S.D.; Trivedi, H.R.; Parmar, D.M.; Dalvi, P.S.; Jiyo, C. Impact of proton pump inhibitors on efficacy of clopidogrel: Review of evidence. Indian J. Pharmacol., 2011, 43(2), 183-186.
28. Niitsu, Y.; Jakubowski, J.A.; Sugidachi, A.; Asai, F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Seminars in thrombosis and hemostasis, 2005, 31(2), 184-194.
29. Wallentin, L.; Varenhorst, C.; James, S.; Erlinge, D.; Braun, O.O.; Jakubowski, J.A.; Sugidachi, A.; Winters, K.J.; Siegbahn, A. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur. Heart J., 2008, 29(1):21-30.
30. Mega, J.L.; Close, S.L.; Wiviott, S.D.; Shen, L.; Hockett, R.D.; Brandt, J.T.; Walker, J.R.; Antman, E.M.; Macias, W.L.; Braunwald, E.; et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation, 2009, 119(19), 2553-2560.
31. Schomig, A. Ticagrelor--is there need for a new player in the antiplatelet-therapy field? The New England journal of medicine, 2009, 361(11), 1108-1111.
32. Angiolillo, D.J.; Bhatt, D.L.; Gurbel, P.; Jennings, L.K. Advances in antiplatelet therapy: agents in clinical development. J. Am. Coll. Cardiol., 2009, 103(3 Suppl), 40A-51A.
33. Wiviott, S.D.; Trenk, D.; Frelinger, A.L.; O'Donoghue, M.; Neumann, F.J.; Michelson, A.D.; Angiolillo, D.J.; Hod, H.; Montalescot, G.; Miller, D.L.; et al. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation, 2007, 116(25), 2923-2932.
34. Wiviott, S.D.; Braunwald, E.; McCabe, C.H.; Horvath, I.; Keltai, M.; Herrman, J.P.; Van de Werf, F.; Downey, W.E.; Scirica, B.M.; Murphy, S.A.; et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet, 2008, 371(9621), 1353-1363.
35. Wiviott, S.D.; Braunwald, E.; Angiolillo, D.J.; Meisel, S.; Dalby, A.J.; Verheugt, F.W.; Goodman, S.G.; Corbalan, R.; Purdy, DA.; Murphy, S.A.; et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation, 2008, 118(16), 1626-1636.
36. Sugidachi, A.; Ogawa, T.; Kurihara, A.; Hagihara, K.; Jakubowski, J.A.; Hashimoto, M.; Niitsu, Y.; Asai, F. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J. Thromb. Haemost., 2007, 5(7), 1545-1551.
37. Mahoney, E.M.; Wang, K.; Arnold, S.V.; Proskorovsky, I.; Wiviott, S.; Antman, E.; Braunwald, E.; Cohen, D.J. Costeffectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation, 2010, 121(1), 71-79.
38. Lieu, H.D.; CP, Andre, P.; Leese, P.T.; Romanko, K.; Phillips, D.R.; Jurek, M.; Meloni, A.; Hutchaleelaha, A.; Gretler, D.D. Initial intravenous experience with PRT060128 (PRT128), an orally-available, direct-acting, and reversible P2Y12 inhibitor. J. Thromb. Haemost., 2007, 5(supplement 2).
39. Berger, J.S.; Roe, M.T.; Gibson, C.M.; Kilaru, R.; Green, C.L.; Melton, L.; Blankenship, J.D.; Metzger, D.C.; Granger, C.B.; Gretler, D.D.; et al. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am. Heart J., 2009, 158(6), 998-1004 e1001.
40. Leonardi, S.; Rao, S.V.; Harrington, R.A.; Bhatt, D.L.; Gibson, C.M.; Roe, M.T.; Kochman, J.; Huber, K.; Zeymer, U.; Madan, M.; et al. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am. Heart J., 2010, 160(1), 65-72.
41. Cannon, C.P.; Husted, S.; Harrington, R.A.; Scirica, B.M.; Emanuelsson, H.; Peters, G.; Storey, R.F. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J. Am. Coll. Cardiol., 2007, 50(19), 1844-1851.
42. Gurbel, P.A.; Bliden, K.P.; Butler, K.; Tantry, U.S.; Gesheff, T.; Wei, C.; Teng, R.; Antonino, M.J.; Patil, S.B.; Karunakaran, A.; et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation, 2009, 120(25), 2577-2585.
43. Wallentin, L.; Becker, R.C.; Budaj, A.; Cannon, C.P.; Emanuelsson, H.; Held, C.; Horrow, J.; Husted, S.; James, S.; Katus, H.; et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. The New England journal of medicine, 2009, 361(11), 1045-1057.
44. Brown, R.A.; Spina, D.; Page, C.P. Adenosine receptors and asthma. British journal of pharmacology, 2008, 153(1):S446-456.
45. Lerman, B.B.; Belardinelli, L. Cardiac electrophysiology of adenosine. Basic and clinical concepts. Circulation, 1991, 83(5), 1499-1509.
46. Gottlieb, S.S.; Brater, D.C.; Thomas, I.; Havranek, E.; Bourge, R.; Goldman, S.; Dyer, F.; Gomez, M.; Bennett, D.; Ticho, B.; et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation, 2002, 105(11), 1348-1353.
47. Harrington, R.A.; Stone, G.W.; McNulty, S.; White, H.D.; Lincoff, A.M.; Gibson, C.M.; Pollack, C.V.; Jr., Montalescot, G.; Mahaffey, K.W.; Kleiman, N.S.; et al. Platelet inhibition with cangrelor in patients undergoing PCI. The New England journal of medicine, 2009, 361(24), 2318-2329.
48. Storey, R.F.; Oldroyd, K.G.; Wilcox, R.G. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. J. Thromb. Haemost., 2001, 85(3), 401-407.
49. Wang, K.; Zhou, X.; Zhou, Z.; Tarakji, K.; Carneiro, M.; Penn, M.S.; Murray, D.; Klein, A.; Humphries, R.G.; Turner, J.; et al. Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model. Arteriosclerosis, thrombosis, and vascular biology, 2003, 23(2), 357-362.
50. Bhatt, D.L.; Lincoff, A.M.; Gibson, C.M.; Stone, G.W.; McNulty, S.; Montalescot, G.; Kleiman, N.S.; Goodman, S.G.; White, H.D.; Mahaffey, K.W.; et al. Intravenous platelet blockade with cangrelor during PCI. The New England journal of medicine, 2009, 361(24), 2330-2341.
51. Albelda, S.M.; Buck, C.A. Integrins and other cell adhesion molecules. FASEB J., 1990, 4(11), 2868-2880.
52. Neumann, F.J.; Blasini, R.; Schmitt, C.; Alt, E.; Dirschinger, J.; Gawaz, M.; Kastrati, A.; Schomig, A. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation, 1998, 98(24), 2695-2701.
53. Moser, M.; Bertram, U.; Peter, K.; Bode, C.; Ruef, J. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. J. Cardiovasc. Pharmacol., 2003, 41(4), 586-592.
54. Goto, S.; Tamura, N.; Ishida, H. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J. Am. Coll. Cardiol., 2004, 44(2), 316-323.
55. Keeley, E.C.; Boura, J.A.; Grines, C.L. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet, 2006, 367(9510), 579-588.
56. Ellis, S.G.; Tendera, M.; de Belder, M.A.; van Boven, A.J.; Widimsky, P.; Janssens, L.; Andersen, H.R.; Betriu, A.; Savonitto, S.; Adamus, J.; et al. Facilitated PCI in patients with ST-elevation myocardial infarction. The New England Journal of Medicine, 2008, 358(21), 2205-2217.
57. Montalescot, G.; Antoniucci, D.; Kastrati, A.; Neumann, F.J.; Borentain, M.; Migliorini, A.; Boutron, C.; Collet, J.P.; Vicaut, E. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur. Heart J., 2007, 28(4), 443-449.
58. Rakowski, T.; Siudak, Z.; Dziewierz, A.; Birkemeyer, R.; Legutko, J.; Mielecki, W.; Depukat, R.; Janzon, M.; Stefaniak, J.; Zmudka, K.; et al. Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER registry. Am. Heart J., 2009, 158(4), 569-575.
59. Van't Hof, A.W.; Ten Berg, J.; Heestermans, T.; Dill, T.; Funck, R.C.; van Werkum, W.; Dambrink, J.H.; Suryapranata, H.; van Houwelingen, G.; Ottervanger, J.P.; et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet, 2008, 372(9638), 537-546.
60. Stone, G.W.; Witzenbichler, B.; Guagliumi, G.; Peruga, J.Z.; Brodie, B.R.; Dudek, D.; Kornowski, R.; Hartmann, F.; Gersh, B.J.; Pocock, S.J.; et al. Bivalirudin during primary PCI in acute myocardial infarction. The New England journal of medicine, 2008, 358(21), 2218-2230.
61. Mehilli, J.; Kastrati, A.; Schulz, S.; Frungel, S.; Nekolla, S.G.; Moshage, W.; Dotzer, F.; Huber, K.; Pache, J.; Dirschinger, J.; et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation, 2009, 119(14), 1933-1940.
62. Boersma, E.; Harrington, R.A.; Moliterno, D.J.; White, H.; Theroux, P.; Van de Werf, F.; de Torbal, A.; Armstrong, P.W.; Wallentin, L.C.; Wilcox, R.G.; et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet, 2002, 359(9302), 189-198.
63. Kastrati, A.; Mehilli, J.; Neumann, F.J.; Dotzer, F.; ten Berg, J.; Bollwein, H.; Graf, I.; Ibrahim, M.; Pache, J.; Seyfarth, M.; et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA, 2006, 295(13), 1531-1538.
64. Stone, G.W.; Bertrand, M.E.; Moses, J.W.; Ohman, E.M.; Lincoff, A.M.; Ware, J.H.; Pocock, S.J.; McLaurin, B.T.; Cox, D.A.; Jafar, M.Z.; et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA, 2007, 297(6), 591-602.
65. Aroney, C.N.; Aylward, P.; Chew, D.P.; Huang, N.; Kelly, A.M.; White, H.; Wilson, M. 2007 addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Guidelines for the management of acute coronary syndromes 2006. Med. J. Aust., 2008, 188(5), 302-303.
66. Deibele, A.J.; Jennings, L.K.; Tcheng, J.E.; Neva, C.; Earhart, A.D.; Gibson, C.M. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. Circulation, 2010, 121(6), 784-791.
67. Thiele, H.; Schindler, K.; Friedenberger, J.; Eitel, I.; Furnau, G.; Grebe, E.; Erbs, S.; Linke, A.; Mobius-Winkler, S.; Kivelitz, D.; et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation, 2008, 118(1), 49-57.
68. Wohrle, J.; Grebe, O.C.; Nusser, T.; Al-Khayer, E.; Schaible, S.; Kochs, M.; Hombach, V.; Hoher, M. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation, 2003, 107(14), 1840-1843.
69. Kato, Y.; Kita, Y.; Hirasawa-Taniyama, Y.; Nishio, M.; Mihara, K.; Ito, K.; Yamanaka, T.; Seki, J.; Miyata, S.; Mutoh, S. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur. J. Pharm., 2003, 473(2-3), 163-169.
70. Angiolillo, D.J.; Capodanno, D.; Goto, S. Platelet thrombin receptor antagonism and atherothrombosis. Eur. Heart J., 2010, 31(1), 17-28.
71. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. American heart journal, 2009, 158(3), 327-334 e324.
72. Goto, S.; Ogawa, H.; Takeuchi, M.; Flather, M.D.; Bhatt, D.L. Double-blind, placebo-controlled Phase II studies of the proteaseactivated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur. Heart J., 31(21):2601-2613.
73. Wiviott, S.D.; Flather, M.D.; O'Donoghue, M.L.; Goto, S.; Fitzgerald, D.J.; Cura, F.; Aylward, P.; Guetta, V.; Dudek, D.; Contant, C.F.; et al. Randomized Trial of Atopaxar in the Treatment of Patients With Coronary Artery Disease: The Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease Trial. Circulation, 2011, 123(17), 1854-1863.
74. O'Donoghue, M.L.; Bhatt, D.L.; Wiviott, S.D.; Goodman, S.G.; Fitzgerald, D.J.; Angiolillo, D.J.; Goto, S.; Montalescot, G.; Zeymer, U.; Aylward, P.E.; et al. Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes: The Lessons From Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes Trial. Circulation, 2011, 123(17), 1843-1853.